Alzamend Neuro News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.11.24	EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential (Benzinga)
16.10.24	EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's (Benzinga)
20.08.24	Nvidia, AMD, Alzamend Neuro, Palo Alto Networks, Tesla: Why These 5 Stocks Are On Investors' Radars Today (Benzinga)
19.08.24	Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details (Benzinga)
05.08.24	EXCLUSIVE: Alzamend Neuro To Assess AL001 Alzheimer's Candidate Against Commonly Marketed Lithium Salt In Phase 2 Head-To-Head Study (Benzinga)
22.05.24	Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel (Businesswire)
14.05.24	Alzamend Neuro Announces Initial Closing of Private Placement (Businesswire)
09.05.24	Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million (Businesswire)
09.05.24	EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares (Benzinga)
07.05.24	Alzamend Neuro Halts Equity Offering Program, Prioritizing Shareholder Value Amid Strategic Shift, Shares Slide (Benzinga)
07.05.24	Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program (Businesswire)
24.04.24	Alzamend Neuro And 2 Other Stocks Under $5 Insiders Are Buying (Benzinga)
10.01.24	Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying (Benzinga)
11.12.23	Alzamend Neuro Receives FDA "Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients (Businesswire)
20.11.23	Alzamend Neuro Receives FDA "Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients (Businesswire)
16.11.23	Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement (Businesswire)
13.11.23	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001 (Businesswire)
30.10.23	Alzamend Neuro Announces Reverse Stock Split (Businesswire)
23.10.23	Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001 (Businesswire)
02.10.23	Alzamend Neuro Receives FDA "Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Businesswire)
22.09.23	Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement (Businesswire)
30.08.23	Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients (Businesswire)
22.06.23	Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001 (Businesswire)
13.06.23	Alzamend Neuro CEO Stephan Jackman to Participate on the "Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference (Businesswire)
03.04.23	Alzamend Neuro Announces the Initiation of a Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type (Businesswire)
22.03.23	Alzamend Neuro Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s (Businesswire)
16.03.23	Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business Update (Businesswire)
26.01.23	Alzamend Neuro to Present at Sequire Biotechnology Conference (Businesswire)
04.01.23	Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase I/IIA Clinical Trial (Businesswire)
15.11.22	Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline (Businesswire)
05.10.22	Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects (Businesswire)
29.09.22	Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type (Businesswire)
22.09.22	Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement (Businesswire)
18.07.22	Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Businesswire)
03.06.22	Alzamend Neuro to Present at the 12th Annual LD Micro Invitational (Businesswire)
17.05.22	Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder (Businesswire)
05.05.22	Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s (Businesswire)
28.04.22	Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s (Businesswire)
11.04.22	Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s (Businesswire)
04.04.22	Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board (Businesswire)
20.12.21	Top Biotech IPOs Of 2021 That Soared As Much As 500% (RTTNews)
15.12.21	Pre-market Movers: IDRA, GRTX, SEAC, ALZN, SIDU… (RTTNews)
14.12.21	Pre-market Movers: XCUR, MIND, NES, APTO, ALZN… (RTTNews)
19.11.21	Pre-market Movers: TUSK, AQB, LGVN, CNTB, UWMC… (RTTNews)
11.11.21	Pre-market Movers: FOSL, AFRM, RWLK, BYND, CRCT… (RTTNews)
23.06.21	Pre-market Movers: ACST, TENX, GMTX, EYES… (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Alzamend Neuro Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten